Baseline Hypozincemia Predicts Clinical Relapse in Patients with Ulcerative Colitis in Remission
Abstract
Objective Ulcerative colitis (UC) follows a relapsing-remitting course. Identifying modifiable clinical relapse prognostic factors remains challenging. Patients with inflammatory bowel disease commonly exhibit zinc deficiencies. In this study, we aimed to determine whether hypozincemia is independently associated with the risk of relapse. Methods Baseline serum zinc levels were measured in patients with UC in clinical remission (i.e., partial Mayo score <3) from a single center between April 2015 and March 2025. Patients were classified as having hypozincemia (serum zinc <80 μg/dL) or normozincemia (serum zinc ≥80 μg/dL). The primary outcome was clinical relapse within one year. Relapse-free survival was assessed using a Kaplan-Meier survival analysis. Independent predictors of relapse were evaluated using multivariable Cox proportional hazards models adjusted for inflammatory markers, serum albumin levels, and previous biologic therapy. Results Overall, 102 patients were included (50 with hypozincemia and 52 with normozincemia). The hypozincemia group experienced clinical relapse more frequently than the normozincemia group (74.0% vs. 34.6%, P<0.001). Relapse-free survival was significantly shorter in patients with hypozincemia (log-rank: P<0.001). A multivariable Cox regression analysis showed that normozincemia was independently associated with a reduced relapse risk (adjusted hazard ratio, 0.42; 95% confidence interval, 0.24-0.74; P=0.003). C-reactive protein and serum albumin were not significant predictors. Serum zinc levels were weakly correlated with the inflammatory biomarkers. Conclusion Hypozincemia was independently associated with an increased clinical relapse risk in patients with UC in remission. Baseline assessment of serum zinc levels may provide additional prognostic information beyond that of conventional inflammatory and nutritional markers.
Related
- Exploratory baseline mucosal transcriptomics and vedolizumab response in ulcerative colitis
- Leukemic fitness predicts treatment-free remission and guides adaptive therapy in chronic myeloid leukemia
- Machine learning predicts relapse after anti-TNF withdrawal in ulcerative colitis using rectal biopsy transcriptomics
- Baseline mucosal transcriptomic endotypes stratify healing capacity and biologic therapy outcomes in ulcerative colitis: an integrative multi-cohort study
- Longitudinal Metaproteomic and Lysine Crotonylation Remodeling Defines Clinical Response to Fecal Microbiota Transplantation in Ulcerative Colitis
BibTeX
@article{miyaguchi2026baseline,
title = {{Baseline Hypozincemia Predicts Clinical Relapse in Patients with Ulcerative Colitis in Remission}},
author = {Kazuya Miyaguchi and Yoshikazu Tsuzuki and Hisashi Matsumoto and Yukiko Oya and Maiko Osawa and Rie Shiomi and Keiji Yamamoto and Yuki Shiko and Hiroyuki Imaeda},
journal = {Internal Medicine},
year = {2026},
month = jul,
doi = {10.2169/internalmedicine.7752-26},
url = {https://www.jstage.jst.go.jp/article/internalmedicine/advpub/0/advpub_7752-26/_article},
note = {CC BY-NC-ND},
}
RIS
TY - JOUR
TI - Baseline Hypozincemia Predicts Clinical Relapse in Patients with Ulcerative Colitis in Remission
AU - Kazuya Miyaguchi
AU - Yoshikazu Tsuzuki
AU - Hisashi Matsumoto
AU - Yukiko Oya
AU - Maiko Osawa
AU - Rie Shiomi
AU - Keiji Yamamoto
AU - Yuki Shiko
AU - Hiroyuki Imaeda
PY - 2026
DA - 2026/07/25
JO - Internal Medicine
DO - 10.2169/internalmedicine.7752-26
UR - https://www.jstage.jst.go.jp/article/internalmedicine/advpub/0/advpub_7752-26/_article
AB - Objective Ulcerative colitis (UC) follows a relapsing-remitting course. Identifying modifiable clinical relapse prognostic factors remains challenging. Patients with inflammatory bowel disease commonly exhibit zinc deficiencies. In this study, we aimed to determine whether hypozincemia is independently associated with the risk of relapse. Methods Baseline serum zinc levels were measured in patients with UC in clinical remission (i.e., partial Mayo score <3) from a single center between April 2015 and March 2025. Patients were classified as having hypozincemia (serum zinc <80 μg/dL) or normozincemia (serum zinc ≥80 μg/dL). The primary outcome was clinical relapse within one year. Relapse-free survival was assessed using a Kaplan-Meier survival analysis. Independent predictors of relapse were evaluated using multivariable Cox proportional hazards models adjusted for inflammatory markers, serum albumin levels, and previous biologic therapy. Results Overall, 102 patients were included (50 with hypozincemia and 52 with normozincemia). The hypozincemia group experienced clinical relapse more frequently than the normozincemia group (74.0% vs. 34.6%, P<0.001). Relapse-free survival was significantly shorter in patients with hypozincemia (log-rank: P<0.001). A multivariable Cox regression analysis showed that normozincemia was independently associated with a reduced relapse risk (adjusted hazard ratio, 0.42; 95% confidence interval, 0.24-0.74; P=0.003). C-reactive protein and serum albumin were not significant predictors. Serum zinc levels were weakly correlated with the inflammatory biomarkers. Conclusion Hypozincemia was independently associated with an increased clinical relapse risk in patients with UC in remission. Baseline assessment of serum zinc levels may provide additional prognostic information beyond that of conventional inflammatory and nutritional markers.
SN - 1349-7235
SN - 0918-2918
ER -